A new round of band volume procurement officially launched! The latest 481 review drug complete list way out

So what is the status of the quality evaluation of generic drugs so far as a ticket to enter the band procurement? What new progress has been made in the declaration and adoption of the conformity evaluation of generic drugs in December? The GBI SOURCE database takes you to learn more!, December 2019 new through the generic drug consistency evaluation product regulations
as of December 30, 2019, December 20 new product regulations through the generic drug consistency evaluation, of which 15 product rules for 289 catalog varieties, The new generic scove swashest in December 2019According to the GBI SOURCE database, as of December 30, 2019, 18 new generic drug consistency evaluation rules were added in December, five of which were included in the China List of Drugs listed3The consistency evaluation of generic drugs through enterprises up to 3 and above product regulations
so far, through the consistency evaluation of generic drugs or as if through the consistency evaluation of generic drugs through the enterprise up to 3 and above a total of 47 product regulations, as shown belowIV, the overall progress of generic drug consistency evaluationAccording to GBI SOURCE database shows that as of December 30, 2019, CDE related to generic drug consistency evaluation cumulative acceptance number has reached 1855, involving 480 enterprises 364 varieties, there are currently 481 product rules passed or see the same as the generic drug consistency evaluationIn addition to the above 47 product regulations through the number of enterprises reached more than 3, there are 44 product regulations have 2 enterprises through, 173 product regulations have 1 enterprise through (detailed list see the table below)Fifth and CDE acceptance of generic drug consistency evaluation trendAccording to the results of the GBI SOURCE database (Drug Declaration Statistics) tool, CDE received 97 new applications for generic drug consistency evaluation in December 2019( as of December 30), an increase of 27.6% compared to November;